The MEDIOLA ovarian study evaluated the association of the anti-PD-L1 durvalumab and PARPi olaparib in heavily pretreated patients with platinum-sensitive (n = 5) or resistant (n = 30) ovarian cancer, including six germline BRCA1/2 (gBRCA)-mutant patients. Here, BRCA1 is linked to ovarian carcinoma.